Companies: 10,795·Total market cap: $144.5T
Humacyte, Inc.

Humacyte, Inc.

HUMANASDAQHealthcare● Active
$1.45
+$0.07(+5.07%)
Market Cap$243600000
P/E Ratio—
52W High$2.84
52W Low$0.547
Cash on HandFinancialsRevenue

Humacyte, Inc. (HUMA) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

HUMA · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$50.5M▲ +12.4% vs prior year
FY · as of Dec 31, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$50.5M
cashAndCashEquivalents
Short-Term Investments
$0
shortTermInvestments
YoY Change vs Prior Year
+12.4%
vs prior fiscal year
Latest Quarter
$48.5M
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$50.5MCash on Hand
Total Debt$64.8MTotal Debt
Net Cash / Net Debt−$14.3MNet Debt Position
Cash vs Debt Ratio
Cash 44%Debt 56%

Humacyte, Inc. carries a net debt position of $14.3M. Total debt ($64.8M) exceeds cash on hand ($50.5M). Humacyte, Inc. cash vs debt ratio: 44% cash / 56% debt.

Net Cash = Cash & ST Investments − Total Debt$50.5M − $64.8M = −$14.3M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
HUMA annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$50.5M+12.4%
Dec 31, 2024$44.9M-44.1%
Dec 31, 2023$80.4M-47.0%
Dec 31, 2022$151.9M-32.6%
Dec 31, 2021$225.5M+464.8%
HUMA cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.6%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Humacyte, Inc.
Humacyte, Inc.YOU
HUMA
$50.5M20.8%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Humacyte, Inc. (HUMA) cash on hand as of December 31, 2025 is $50.5M, comprising $50.5M in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Humacyte, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Humacyte, Inc. cash reserves or cash position.

Humacyte, Inc. annual cash on hand history shows increased +12.4% in 2025: increased +12.4% in 2025. Humacyte, Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Humacyte, Inc. carries total debt of $64.8M against cash of $50.5M, resulting in a net debt position of -$14.3M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

HUMA cash on hand · 5 questions

As of December 31, 2025, Humacyte, Inc. (HUMA) has $50,497,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $50,497,000 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $48,539,000. Data sourced from the annual 10-K filing via FMP.

HUMA cash on handHUMA cash reservesHUMA cash 2025how much cash does HUMA have

▸ Source: FMP /balance-sheet-statement · US GAAP · Humacyte, Inc. · Humacyte, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025